Immune checkpoint inhibitors (ICIs) for lung cancer (LC) treatment have a more favorable safety profile and improved patient reported outcomes (PROs) compared to chemotherapy, suggesting that ICIs are advantageous for older populations. The impact of ICIs on PROs, clinical outcomes, and age in LC patients remains to be established. We examined associations between age and PROs, emergency department (ED) visits, and hospitalizations in LC patients receiving ICIs.

中文翻译：

---

接受免疫检查点抑制剂的肺癌患者的年龄与患者报告的结果、急诊就诊和住院之间的关联

与化疗相比，用于肺癌 (LC) 治疗的免疫检查点抑制剂 (ICIs) 具有更有利的安全性和改善的患者报告结果 (PRO)，这表明 ICI 对老年人群有利。ICI 对 LC 患者 PRO、临床结果和年龄的影响仍有待确定。我们研究了接受 ICI 的 LC 患者的年龄与 PRO、急诊科 (ED) 就诊和住院情况之间的关联。